Co-Diagnostics Q2 net loss narrows to $6.3M; FDA 510(k) submitted for Flu/RSV test

Co-Diagnostics, Inc.

Revenue $0.17M vs $0.16M YoY; net loss $6.3M ($1.46/share) vs $7.7M ($7.00) prior year.
Operating loss $6.2M, improved from $8.1M; adjusted EBITDA loss $5.8M vs $7.2M; cash $3.6M.
Submitted FDA 510(k) for Flu A/B & RSV test on PCR Pro; clinical study 1,400+ patients, 27 analytical studies, 10,000+ runs.
Advanced Saudi manufacturing: industrial site approval and lease in Sudair Industrial City; distribution agreement in Mexico.
Appointed Wes Lindsey, Ph.D. as Chief Scientific Officer; initiated TB studies in India via CoSara.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.